 
                                                                                                    01/29/2025
                                        Rachel Steele, OD, and Mohammad Rafieetary, OD, (of Charles Retina Institute) present a case report of a patient with hydroxychloroquine maculopathy and discuss screening protocols for limiting risk.
While hydroxychloroquine (HQC) has demonstrated the ability to reduce inflammation in individuals with autoimmune disorders, the risk for HQC maculopathy is a very real threat — one that necessitates careful adherence to dosing guidelines and monitoring protocols. Retinal toxicity due to long-term HQC therapy is a well-documented complication with the potential to cause irreversible vision loss, which may progress for years after ceasing the drug.
Although the overall incidence of retinal toxicity is low with appropriate dosing, a combination of subjective and objective tools during eye examination can detect functional and structural changes indicating HQC maculopathy. Advances in imaging modalities allow earlier disease detection and improved visual outcomes for these patients. 
Read here: https://bit.ly/3VAOVrS
                                     
 
                                                                                                     
                                                                                                     
                                                                                                     
                                                                                                     
                                                                                                     
                                                                                                     
                                                                                                     
                                         
   
   
   
   
     
   
   
  